

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified
prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new
custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days
of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental
spectra
NEWS 16 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.
applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new
predefined hit display formats

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 17:00:01 ON 27 APR 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:00:17 ON 27 APR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 APR 2008 HIGHEST RN 1017464-96-8

DICTIONARY FILE UPDATES: 25 APR 2008 HIGHEST RN 1017464-96-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> s SKI-606


176 SKI
2 SKIS
178 SKI
(SKI OR SKIS)

4832 606

L1 1 SKI-606
(SKI(W)606)

=> d scan l1

L1 1 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Quinolonecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-
7-[3-(4-methyl-1-piperazinyl)propoxy]-
MF C26 H29 Cl2 N5 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED


```

=> s "SKI 606"
      176 "SKI"
      2 "SKIS"
      178 "SKI"
      ("SKI" OR "SKIS")
4832 "606"
L2 1 "SKI 606"
    ("SKI"(W) "606")

=> d scan

L2 1 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-
   7-[3-(4-methyl-1-piperazinyl)propoxy]-
MF C26 H29 Cl2 N5 O3
CI COM

```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```

=> file caplus medline embase biosis scisearch
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                    ENTRY        SESSION
FULL ESTIMATED COST                               23.82          24.03

```

FILE 'CAPLUS' ENTERED AT 17:04:21 ON 27 APR 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 17:04:21 ON 27 APR 2008

FILE 'EMBASE' ENTERED AT 17:04:21 ON 27 APR 2008
 Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 17:04:21 ON 27 APR 2008
 Copyright (c) 2008 The Thomson Corporation

=> s l2

L3 235 L2

=> d scan l3

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
TI A novel 4-anilino-3-quinolinecarbonitrile dual src and abl kinase
inhibitor (SKI-606) has in vitro activity on CML Ph plus Blast cells
resistant to imatinib.

IT Miscellaneous Descriptors
apoptosis; cell viability; cell cycle progression

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

CC 1-0 (Pharmacology)

TI Dual Src and Abl kinase inhibitor treatment of solid tumors treatment of
CML and Ph+ ALL

ST review bosutinib solid tumor chronic myelogenous acute lymphoblastic
leukemia

IT Acute lymphocytic leukemia

Chronic myeloid leukemia

Human

(dual Src and Abl kinase inhibitor bosutinib could be useful in
treatment of solid tumors, chronic myeloid leukemia and Ph+ acute
lymphoblastic leukemia in human)

IT Neoplasm

(solid; dual Src and Abl kinase inhibitor bosutinib could be useful in
treatment of solid tumors, chronic myeloid leukemia and Ph+ acute
lymphoblastic leukemia in human)

IT 98037-52-6, Abl kinase 141349-89-5, Src kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(dual Src and Abl kinase inhibitor bosutinib could be useful in
treatment of solid tumors, chronic myeloid leukemia and Ph+ acute
lymphoblastic leukemia in human)

IT 380843-75-4, Bosutinib

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(dual Src and Abl kinase inhibitor bosutinib could be useful in
treatment of solid tumors, chronic myeloid leukemia and Ph+ acute
lymphoblastic leukemia in human)

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

TI Structural insights into the ATP binding pocket of the anaplastic lymphoma
kinase by site-directed mutagenesis, inhibitor binding analysis, and
homology modeling.

IT Methods & Equipment

homology modelling: mathematical and computer techniques; inhibitor
binding analysis: laboratory techniques

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM C12N

CC 1-6 (Pharmacology)

Section cross-reference(s): 3, 7, 14

TI Binding and inhibitory assays for detecting BCR-ABL kinase mutations
associated with sensitivity to inhibitor-based anti leukemic drugs

ST binding inhibitory assay BCABL kinase mutation antileukemic drug
sensitivity; human sequence BCABL protein kinase mutation

IT Chimeric gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (BCR-ABL; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)

IT Enzyme functional sites
 (active; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)

IT Acute lymphocytic leukemia
 Acute myeloid leukemia
 Antitumor agents
 Chemotherapy
 Chronic myeloid leukemia
 Drug resistance
 Human
 Protein sequences
 (binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)

IT Molecular association
 (inhibitor-kinase domain interaction; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)

IT Protein motifs
 (kinase motif, mutations at; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)

IT Animal cell
 (mammalian, expressing BCR-ABL polypeptide; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)

IT Diagnosis
 (mol.; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)

IT Mutation
 (substitution; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)

IT 936654-11-4 936654-12-5 936654-13-6 936654-14-7 936654-15-8
 936654-16-9 936654-17-0
 RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (amino acid sequence; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)

IT 152459-95-5, Imatinib 287204-45-9, PD180970 302962-49-8 379231-04-6, AZD0530 380843-75-4, SKI606 497152-38-2, CGP76030 641571-10-0, AMN107 845895-51-4, AP23464
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)

IT 98037-52-6, ABL protein kinase
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (inhibitors of; binding and inhibitory assays for detecting BCR-ABL kinase mutations associated with sensitivity to inhibitor-based anti leukemic drugs)

IT 72-19-5, L-Threonine, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (position 315, mutated to Ala; binding and inhibitory assays for
 detecting BCR-ABL kinase mutations associated with sensitivity to
 inhibitor-based anti leukemic drugs)

IT 63-91-2, L-Phenylalanine, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (position 317, mutated to Ile, Val, Ser or Leu; binding and inhibitory
 assays for detecting BCR-ABL kinase mutations associated with sensitivity
 to inhibitor-based anti leukemic drugs)

IT 936663-40-0 936663-41-1 936663-42-2 936663-43-3 936663-44-4
 936663-45-5 936663-46-6
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; binding and inhibitory assays for
 detecting BCR-ABL kinase mutations associated with sensitivity to
 inhibitor-based anti leukemic drugs)

IT 936663-47-7 936663-48-8 936663-49-9 936663-50-2 936663-51-3
 936666-03-4 936666-04-5
 RL: PRP (Properties)
 (unclaimed sequence; binding and inhibitory assays for detecting
 BCR-ABL kinase mutations associated with sensitivity to inhibitor-based
 anti leukemic drugs)

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
 TI A Dual Src/Abl Kinase Inhibitor Causes Regression of CML Xenografts in
 Nude Mice.

IT Miscellaneous Descriptors
 drug resistance mechanism; tumor regression

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
 CC 63-6 (Pharmaceuticals)

TI Ocular device coated with kinase inhibitors to treat and prevent posterior
 capsule opacification

ST ocular device kinase inhibitor coating posterior capsule opacification

IT Cell migration
 Coating materials
 Controlled-release drug delivery systems
 Epithelium
 Eye, disease
 Mesenchyme
 Ophthalmic drug inserts
 Pharmaceutical implants
 (ocular device coated with kinase inhibitors to treat and prevent
 posterior capsule opacification)

IT Fibronectins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ocular device coated with kinase inhibitors to treat and prevent
 posterior capsule opacification)

IT Opacity
 (opacification, eye disease; ocular device coated with kinase
 inhibitors to treat and prevent posterior capsule opacification)

IT α -Actins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (smooth muscle; ocular device coated with kinase inhibitors to treat
 and prevent posterior capsule opacification)

IT 142243-02-5, ERK 165245-96-5, p38 Kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ocular device coated with kinase inhibitors to treat and prevent
 posterior capsule opacification)

IT 172889-26-8, PP1
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
 (ocular device coated with kinase inhibitors to treat and prevent
 posterior capsule opacification)

IT 109511-58-2, U0126 152121-30-7, SB202190 152121-47-6, SB203580
 167869-21-8, PD98059 330161-87-0, SU6656 380843-75-4, SKI606
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ocular device coated with kinase inhibitors to treat and prevent
 posterior capsule opacification)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 235 ANSWERS SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
 AN 2008:162804 SCISEARCH
 GA The Genuine Article (R) Number: 237TE
 TI Preliminary results of a phase 2 study of bosutinib (SKI-
 606), a dual Src/Abl kinase inhibitor, in patients with advanced
 breast cancer.
 CC ONCOLOGY

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
 IC ICM A61K
 CC 8-9 (Radiation Biochemistry)
 Section cross-reference(s): 21
 TI Protection of tissues and cells from cytotoxic effects of ionizing
 radiation by ABL inhibitors
 ST radioprotectant ABL protein kinase inhibitor
 IT Antioxidants
 Human
 Radioprotectants
 Radiotherapy
 (ABL protein kinase inhibitors as radioprotectants)

IT Carotenes, biological studies
 Flavanols
 Flavonoids
 Phenols, biological studies
 Porphyrins
 Ubiquinones
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ABL protein kinase inhibitors as radioprotectants)

IT Transplant and Transplantation
 (bone marrow; ABL protein kinase inhibitors as radioprotectants)

IT Drug delivery systems
 (carriers; ABL protein kinase inhibitors as radioprotectants)

IT Flavones
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (isoflavones; ABL protein kinase inhibitors as radioprotectants)

IT Flavonoids
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oxo dihydro; ABL protein kinase inhibitors as radioprotectants)

IT Bone marrow
 (transplant; ABL protein kinase inhibitors as radioprotectants)

IT 98037-52-6, ABL protein kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ABL protein kinase inhibitors as radioprotectants)

IT 152459-95-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (ABL protein kinase inhibitors as radioprotectants)

IT 334969-03-8 334969-21-0 334969-29-8 592542-77-3 592542-83-1
 851799-24-1 851799-25-2 851799-26-3 851799-27-4 851799-28-5

851799-29-6 851799-30-9 851799-31-0 851799-32-1 851799-33-2
851799-34-3 851799-35-4 851799-36-5 851799-37-6 851799-38-7
851799-39-8 851799-40-1 851799-41-2 851799-42-3 851799-47-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(ABL protein kinase inhibitors as radioprotectants)

IT 88-68-6 109-01-3, 1-Methylpiperazine 124-63-0, Methanesulfonyl
chloride 350-03-8 367-21-5, 3-Chloro-4-fluoroaniline 1194-65-6
1783-81-9, 3-Methylthioaniline 3943-74-6 4432-76-2 5909-24-0
7357-67-7 13794-72-4 33524-31-1 98446-49-2, 2,4-Dichloro-5-
methoxyaniline 148077-69-4 152460-07-6 152460-09-8 152460-10-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(ABL protein kinase inhibitors as radioprotectants)

IT 54105-05-4P 111627-40-8P 179688-52-9P 179688-53-0P 184475-71-6P
185039-29-6P 185039-46-7P 185039-48-9P 185040-32-8P 192997-47-0P
214470-59-4P 214470-66-3P 214470-68-5P 230955-75-6P 788136-89-0P
859504-04-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(ABL protein kinase inhibitors as radioprotectants)

IT 140674-78-8P 184475-35-2P 260415-63-2P 380843-75-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(ABL protein kinase inhibitors as radioprotectants)

IT 50-81-7, Ascorbic acid, biological studies 52-90-4, Cysteine, biological
studies 60-24-2, β -Mercaptoethanol 70-18-8, Glutathione,
biological studies 616-91-1, N-Acetyl-L-cysteine 1406-18-4, Vitamin E
3483-12-3, Dithiothreitol 20537-88-6 23288-49-5, Probulol
25769-03-3, 1-Pyrrolidinecarbodithioic acid 112675-73-7 112676-08-1
173515-05-0 140674-76-6 151391-94-5 152459-77-3 152459-78-4
152459-79-5 152459-80-8 152459-82-0 152459-83-1 152459-84-2
152459-86-4 152459-87-5 152459-88-6 152459-89-7 152459-90-0
152459-91-1 152459-93-3 152459-94-4 152459-96-6 152459-97-7
152459-98-8 152459-99-9 152460-06-5 156790-79-3 156790-80-6
158081-87-9 158081-88-0 158081-89-1 185039-91-2 287204-45-9
305820-77-3 592542-59-1 592542-82-0 592543-23-2 592543-24-3
851799-48-9 851799-49-0 851799-50-3 851799-51-4 859504-11-3
859504-12-4 859504-13-5 859504-14-6 859504-15-7 859504-16-8
859504-17-9 859504-18-0 859504-19-1 859504-20-4 859504-21-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ABL protein kinase inhibitors as radioprotectants)

L3 235 ANSWERS SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2007:364683 SCISEARCH
GA The Genuine Article (R) Number: 111GS
TI In vitro and in vivo activity of SKI-606, a novel
Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic
CC HEMATOLOGY

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
TI 7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as Dual Inhibitors of Src
and Abl Kinases
ST quinolinecarbonitrile arylaminopiperidinylmethoxy prepn Src Abl kinase
inhibitor
IT 98037-52-6, Abl kinase 141349-89-5, Src kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of 7-alkoxy-4-phenylamino-3-quinolinecarbonitriles as
inhibitors of Src and Abl kinases)

IT 380843-75-4P, SKI606 622368-88-1P 622368-90-5P 622368-91-6P

622368-93-8P 622369-16-8P 622369-17-9P 622369-18-0P 622369-19-1P
622369-20-4P 622369-21-5P 622369-26-0P 681819-24-9P 681821-34-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(preparation of 7-alkoxy-4-phenylamino-3-quinolinecarbonitriles as
inhibitors of Src and Abl kinases)

IT 94-05-3, Ethyl (ethoxymethylene)cianoacetate 95-68-1,
2,4-Dimethylaniline 106-52-5, 1-Methyl-4-piperidinol 366-99-4,
3-Fluoro-4-methoxyaniline 554-00-7, 2,4-Dichloroaniline 2401-24-3,
2-Chloro-5-methoxyaniline 5317-33-9, 1-(3-Hydroxypropyl)-4-
methylpiperazine 7037-30-1, 1-Methyl-4-piperidinepropanol 7583-53-1,
1-Methyl-3-piperidinemethanol 20691-89-8, 1-Methyl-4-piperidinemethanol
20845-34-5, 1-Methyl-2-piperidinemethanol 21156-84-3,
1-Methyl-4-piperidineethanol 24313-88-0, 3,4,5-Trimethoxyaniline
50868-72-9, 5-Methoxy-2-methylaniline 98446-49-2, 2,4-Dichloro-5-
methoxyaniline 380844-01-9, 2,4-Dichloro-5-ethoxyaniline 380844-06-4,
5-Methoxy-2,4-Dimethylaniline
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 7-alkoxy-4-phenylamino-3-quinolinecarbonitriles as
inhibitors of Src and Abl kinases)

IT 622369-38-4P 622369-40-8P 622369-46-4P 622369-54-4P 622369-75-9P
622369-76-0P 622369-77-1P 622369-78-2P 622369-79-3P 681819-23-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of 7-alkoxy-4-phenylamino-3-quinolinecarbonitriles as
inhibitors of Src and Abl kinases)

L3 235 ANSWERS SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2006:892418 SCISEARCH
GA The Genuine Article (R) Number: 083YN

TI Structural insights into the ATP binding pocket of the anaplastic lymphoma
kinase by site-directed mutagenesis, inhibitor binding analysis, and
homology modeling

CC CHEMISTRY, MEDICINAL

STP KeyWords Plus (R): RECEPTOR TYROSINE KINASE; NON-HODGKINS-LYMPHOMA;
BCR-ABL; CELL LYMPHOMA; POTENT INHIBITORS; CRYSTAL-STRUCTURE;
INSULIN-RECEPTOR; FUSION PROTEIN; C-ABL; ALK
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
TI SKI-606, a novel Src kinase inhibitor, blocks migration and invasion of
human breast cancer cells.

IT Miscellaneous Descriptors
cell invasion; cell migration

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
IC ICM A61K
CC 1-5 (Pharmacology)
Section cross-reference(s): 7

TI Method of treating inflammatory diseases using tyrosine kinase inhibitors

ST tyrosine kinase inhibitor inflammatory disease therapy

IT Inflammatory bowel disease
(Crohn's disease; treating inflammatory diseases using tyrosine kinase
inhibitors)

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgM; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(I κ B- α (NF- κ B inhibitor α); treating inflammatory diseases using tyrosine kinase inhibitors)

IT Transcription factor STAT
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (STAT3; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Transcription factor STAT
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (STAT3; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Transcription factor STAT
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (STAT5; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Autoimmune disease
 (autoimmune arthritis; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Arthritis
 (autoimmune; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (c-Raf; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (c-abl; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (c-jun; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Autoimmune disease
 (exptl. autoimmune encephalomyelitis; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Encephalomyelitis
 (exptl. autoimmune; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Lung, disease
 (fibrosis; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Cell differentiation
 (monocyte lineage cell; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Interleukin 12
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (p40; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Phosphorylation, biological
 (protein; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Arthritis
 (psoriatic arthritis; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Fibrosis
 (pulmonary; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Macrophage
 (synovial; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Synovial membrane
 (synoviocyte, fibroblast-Like; treating inflammatory diseases using

tyrosine kinase inhibitors)

IT Lupus erythematosus
(systemic; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Anti-inflammatory agents
Antiarthritics
Antirheumatic agents
Apoptosis
Arthritis
Autoimmune disease
B cell (lymphocyte)
Combination chemotherapy
Human
Inflammation
Mast cell
Multiple sclerosis
Oral drug delivery systems
Psoriasis
Rheumatoid arthritis
Scleroderma
Signal transduction
T cell (lymphocyte)
(treating inflammatory diseases using tyrosine kinase inhibitors)

IT Epidermal growth factor receptors
Interleukin 1a
Interleukin 2
Interleukin 4
Interleukin 6
Macrophage colony-stimulating factor receptors
Platelet-derived growth factor receptors
Tumor necrosis factors
c-Kit (protein)
neu (receptor)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treating inflammatory diseases using tyrosine kinase inhibitors)

IT Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type VEGFR-1; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type VEGFR-2; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type VEGFR-3; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Platelet-derived growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(a; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Platelet-derived growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(b; treating inflammatory diseases using tyrosine kinase inhibitors)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(g; treating inflammatory diseases using tyrosine kinase inhibitors)

IT 220127-57-1, Imatinib mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
 (Gleevec; treating inflammatory diseases using tyrosine kinase inhibitors)

IT 80449-02-1, Protein tyrosine kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; treating inflammatory diseases using tyrosine kinase inhibitors)

IT 63551-76-8, Phospholipase Cy 81627-83-0, M-CSF 83869-56-1, Granulocyte-macrophage colony-stimulating factor 90698-26-3, p70s6K 114051-78-4, Lck kinase 141349-89-5, Src kinase 144697-16-5, b-Raf 147230-71-5, Flt3 kinase 148640-14-6 149371-05-1, c-Abl 152478-56-3, JAK1 kinase 155215-87-5, JNK 165245-96-5, p38 MAP kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (treating inflammatory diseases using tyrosine kinase inhibitors)

IT 111358-88-4, Lestaurtinib 120685-11-2, PKC412 122320-73-4, Rosiglitazone 134523-00-5, Atorvastatin 152459-94-4, CGP53716 183321-74-6, Erlotinib 184475-35-2, Gefitinib 185039-91-2, PD166326 187724-61-4, PKI-166 194413-58-6, Semaxanib 212141-54-3, Vatalanib 231277-92-2, Lapatinib 251356-32-8, SU9518 252916-29-3, SU6668 257933-82-7, EKB-569 284461-73-0, Sorafenib 288383-20-0, Cediranib 230962-49-8, Dasatinib 319460-85-0, Axitinib 379231-04-6, AZD0530 380843-75-4, SKI-606 387867-13-2, Tandutinib 443913-73-3, Vandetanib 444731-52-6, Pazopanib 453562-69-1, AMG 706 557795-19-4, Sunitinib 641571-10-0, Nilotinib 679809-58-6, Enoxaparin 692737-80-7, CHIR258 870483-87-7, GW2580 936487-63-7, CP 690
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treating inflammatory diseases using tyrosine kinase inhibitors)

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
 TI Activity of ABL kinase inhibitors in two distinct models of imatinib resistance.

IT Miscellaneous Descriptors
 drug resistance

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
 CC 63-5 (Pharmaceuticals)
 Section cross-reference(s): 1

TI Application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs

ST tyrosine kinase inhibitor dibenzocyclooctadiene lignan antitumor agent synergistic interaction

IT Antitumor agents
 (2C4; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Antitumor agents
 (DB16X; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Antitumor agents
 (PD0173074; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Antitumor agents
 (PK1166; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Antitumor agents
 Combination chemotherapy
 Controlled-release drug delivery systems
 Human
 Neoplasm
 Pharmaceutical capsules
 Pharmaceutical granules

Pharmaceutical injections

Pharmaceutical tablets

Schisandra chinensis

(application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Endothelium

(of human umbilical vein; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Drug interactions

(synergistic; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT Animal cell line

(tumor; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT 7432-28-2, Schisandrol A 51670-40-7, Kadsurin 51670-41-8, Kadsurarin 58546-54-6, Schisandrol B 58546-55-7, Schisantherin B 58546-56-8, Schisantherin A 60546-10-3, Gomisin D 61281-37-6, Schisandrin B 61281-38-7, Schisandrin A 61301-33-5, Schisandrin C 62956-47-2, Gomisin F 62956-48-3, Gomisin G 64917-82-4, Schisantherin D 64917-83-5, Schisantherin E 64938-51-8, Schisantherin C 66056-20-0, Gomisin H 66056-22-2, Angeloylgomisin H 66056-23-3, Benzoylgomisin H 66069-55-4, Tigloylgomisin H 66096-73-9 66096-74-0, Methylschisandrol E 66280-25-9, Gomisin J 69176-51-8, Tiglogomisin P 69176-52-9, Gomisin N 69363-14-0, Gomisin K3 72561-28-5, Angeloylgomisin Q 72960-21-5, Gomisin E 72960-22-6, Gomisin O 73036-31-4, Epigomisin O 75629-20-8, Gomisin K1 75706-12-6, SU101 77165-79-8, Binankadsurin A 77165-80-1 77165-81-2 77174-33-5, Acetylbinankadsurin 77881-08-4, Angelogomisin P 82425-45-4, Gomisin M2 82467-50-3, Gomisin M1 82467-52-5, Isokadsurarin 83864-69-1 83864-70-4 83864-71-5, Benzoylisogomisin O 83864-72-6, Gomisin R 87084-98-8, Neoisostegane 95152-96-8 111358-88-4, CEP-701 115181-68-5, Neokadsurarin 117047-86-6, Schisantherin G 117047-87-7, Schisantherin H 117047-88-8, Schisantherin F 117073-94-6, Schisantherin I 119139-55-8, Interiorin 120685-11-2, PKC412 128324-09-4, Angeloylgomisin R 129385-73-5, Benzoylgomisin Q 129445-43-8 130252-41-4 130252-42-5, Propoxyloxokadsurane 130252-43-6 130252-44-7 130252-45-8 130783-32-3 135432-28-9, Schisantherin J 135541-43-4, Benzoylbinankadsurine A 135541-44-5, Isovaleroylbinankadsurin A 135541-45-6, Isobutyrylbinankadsurin A 143625-35-8, Schisantherin K 149990-51-2, Schisantherin L 149990-52-3, Schisantherin M 150132-86-8, Schisantherin N 150132-87-9, Schisantherin O 180288-69-1, Trastuzumab 183321-74-6, Erlotinib 184475-35-2, Gefitinib 204005-46-9, SU5416 205256-55-9, CT52923 205923-56-4, Erbitux 212142-18-2, PTK787 215543-92-3, SU5402 216974-75-3, Bevacizumab 220127-57-1, Gleevec 231277-92-2, GW-572016 252916-29-3, SU6668 260415-63-2, PD173955 284461-73-0, BAY43-9006 287204-45-9, PD180970 289499-45-2, CI-1033 302962-49-8, BMS354825 339177-26-3, ABX-EGF 341031-54-7, SU11248 379231-04-6, AZD0530 380843-75-4, SKI606 387867-13-2, MLN518 497152-38-2 641571-10-0, AMN107 790713-55-2, AZD 6474 845895-51-4, AP23464 871919-08-3 871919-11-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

IT 80449-02-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitor; application of dibenzocyclooctadiene lignans in preparation of sensitizer of tyrosine kinase inhibitor drugs)

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

TI SKI-606 decreases growth and motility of colorectal cancer cells by

preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling.

IT Methods & Equipment

immunoblotting: laboratory techniques, immunologic techniques;
immunofluorescence staining: laboratory techniques, histology and
cytology techniques, immunologic techniques

IT Miscellaneous Descriptors

cell-to-cell adhesion; transcriptional-adhesive function switch

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

CC 1-0 (Pharmacology)

TI New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance

ST review chronic myelogenous leukemia dasatinib nilotinib bosutinib imatinib antitumor

IT Drug resistance

(antitumor; dasatinib, nilotinib, bosutinib alone or in combination may be novel therapy for management of chronic myelogenous leukemia patient with imatinib resistance)

IT Antitumor agents

Chronic myeloid leukemia

Combination chemotherapy

Human

(dasatinib, nilotinib, bosutinib alone or in combination may be novel therapy for management of chronic myelogenous leukemia patient with imatinib resistance)

IT Antitumor agents

(resistance to; dasatinib, nilotinib, bosutinib alone or in combination may be novel therapy for management of chronic myelogenous leukemia patient with imatinib resistance)

IT 152459-95-5, Imatinib 302962-49-8, Dasatinib 380843-75-4,

Bosutinib 641571-10-0, Nilotinib

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(dasatinib, nilotinib, bosutinib alone or in combination may be novel therapy for management of chronic myelogenous leukemia patient with imatinib resistance)

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

TI SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.

IT Miscellaneous Descriptors

K562 xenografts: regression

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

INCL 514221000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

TI Combinations of BCR-ABL inhibitor and a stem cell selective cytotoxic agent for treating cancer

ST antitumor combination BCR ABL inhibitor stem cell selective cytotoxic

IT Chimeric gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(BCR-ABL; antitumor combinations of BCR-ABL inhibitor and a stem cell selective cytotoxic agent)

IT Antitumor agents

Chronic myeloid leukemia

Combination chemotherapy
Philadelphia chromosome-positive leukemia
Stem cell

(antitumor combinations of BCR-ABL inhibitor and a stem cell selective cytotoxic agent)

IT 152459-95-5, Imatinib 195987-41-8 302962-49-8 379231-04-6, AZD0530
380843-75-4, SKI 606 641571-10-0, AMN-107 845895-51-4, AP23464

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antitumor combinations of BCR-ABL inhibitor and a stem cell selective cytotoxic agent)

L3 235 ANSWERS SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2007:698492 SCISEARCH

GA The Genuine Article (R) Number: 186FK

TI Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing
cells in response to dual inhibitor of SRC and ABL kinases SKI606

CC ONCOLOGY; HEMATOLOGY

ST Author Keywords: chronic myeloid leukemia; p210 tyrosine kinase (TK); SRC
kinases; cyclin-dependent kinase 2 (Cdk2); phosphatidylinositol 3 kinase
(PI-3k)/Akt

STP KeyWords Plus (R): CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA;
TYROSINE KINASE; CYCLE PROGRESSION; DEPENDENT PHOSPHORYLATION;
PHILADELPHIA-CHROMOSOME; INTERLEUKIN-3 RECEPTOR; PROGENITOR CELLS; AKT
ACTIVATION; IMATINIB

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

CC 1-6 (Pharmacology)

TI SKI-606, a Src/Abl Inhibitor with In vivo Activity in Colon Tumor
Xenograft Models

ST colorectal cancer SKI 606 Src Abl

IT Antitumor agents

Human

(SKI-606, a Src/Abl inhibitor with In vivo activity in colon tumor
xenograft models)

IT Gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-abl; SKI-606, a Src/Abl inhibitor with In vivo activity in colon
tumor xenograft models)

IT Gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-src; SKI-606, a Src/Abl inhibitor with In vivo activity in colon
tumor xenograft models)

IT Intestine, neoplasm

(colon; SKI-606, a Src/Abl inhibitor with In vivo activity in colon
tumor xenograft models)

IT 380843-75-4, SKI-606

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(SKI-606, a Src/Abl inhibitor with In vivo activity in colon tumor
xenograft models)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 235 ANSWERS SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2007:362672 SCISEARCH

GA The Genuine Article (R) Number: 111GS

TI A phase 1/2 study of SKI-606, a dual inhibitor of src
and abl kinases, in adult patients with Philadelphia chromosome positive
(Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia
(ALL) relapsed, refractory or intolerant of imatinib.

CC HEMATOLOGY

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM C07D215-38

ICS C07D215-60

INCL 546153000; 546159000

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 45

TI Process for the preparation of 7-substituted 3-quinoline and

3-quinol-4-one carbonitriles via nucleophilic substitution

ST quinoline quinolone carbonitrile prepn halogenation alkylation amine

nucleophilic substitution; quinolinecarbonitrile quinolonecarbonitrile

prepn halogenation alkylation amine nucleophilic substitution

IT Alkylation

Halogenation

Substitution reaction, nucleophilic

(process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

IT Nitriles, preparation

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic

preparation); PREP (Preparation); RACT (Reactant or reagent)

(quinoline product; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

IT Amines, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

IT 7646-69-7, Sodium hydride 7693-26-7, Potassium hydride

RL: RCT (Reactant); RACT (Reactant or reagent)

(base; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

IT 7440-09-7, Potassium, reactions 7440-23-5, Sodium, reactions

RL: RGT (Reagent); RACT (Reactant or reagent)

(base; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

IT 7789-59-5, Phosphoric tribromide 10025-87-3, Phosphoric trichloride

RL: RCT (Reactant); RACT (Reactant or reagent)

(halogenating agent; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

IT 221198-59-0P, 2-Fluoro-1-(2-methoxyethoxy)-4-nitrobenzene 221199-26-4P,

3-Fluoro-4-(2-methoxyethoxy)aniline 423180-28-3P, 4-Chloro-6-methoxy-7-

[(1-methyl-piperidin-4-yl)methoxy]quinoline-3-carbonitrile 622369-35-1P

622369-36-2P 622369-37-3P 622369-38-4P 622369-40-8P 622369-42-0P

622369-44-2P 622369-46-4P 622369-48-6P 622369-49-7P 622369-50-0P

622369-51-1P 622369-52-2P 622369-53-3P 622369-54-4P 622369-55-5P

622369-56-6P 622369-57-7P 622369-59-9P 622369-60-2P 622369-62-4P

622369-63-5P 622369-65-7P 622369-66-8P 622369-67-9P 622369-68-0P,

Ethyl 2-[(1E)-(dimethylamino)methylidene]amino]-4-fluorobenzoate

622369-69-1P 622369-70-4P 622369-71-5P 622369-73-7P 622369-74-8P

622369-75-9P 622369-76-0P 622369-77-1P 622369-78-2P 622369-79-3P

622369-82-8P 622369-84-0P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic

preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

IT 622369-64-6P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic

preparation); PREP (Preparation); RACT (Reactant or reagent)

(process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

IT 622369-72-6P, 7-(2-Methoxyethoxy)-4-oxo-1,4-dihydroquinoline-3-

carbonitrile

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

IT 87-13-8, Diethylethoxymethylene malonate 94-05-3, Ethyl(ethoxymethylene)cianoacetate 100-72-1, Tetrahydropyran-2-methanol 109-01-3, N-Methylpiperazine 109-55-7, N,N-Dimethyl-1,3-propanediamine 109-86-4, 2-(Methoxy)ethanol 111-77-3, 2-(2-Methoxyethoxy)ethanol 139-59-3, 4-Phenoxyaniline 366-99-4, 3-Fluoro-4-methoxyaniline 446-32-2, 2-Amino-4-fluorobenzoic acid 554-00-7, 2,4-Dichloroaniline 622-40-2, 4-(2-Hydroxyethyl)morpholine 626-64-2, 4-Hydroxypyridine 636-72-6, 2-Thiophenemethanol 764-01-2, 2-Butyn-1-ol 930-69-8, Sodium thiophenoxide 1003-03-8, Cyclopentylamine 1188-33-6, Dimethylformamide diethyl acetal 3179-63-3 4543-96-8, N,N,N'-Trimethyl-1,3-propanediamine 5317-33-9, 3-[(4-Methyl)piperazin-1-yl]propanol 6482-24-2, 2-Bromoethyl methyl ether 7583-53-1, 1-Methylpiperidine-3-methanol 13349-82-1, 2-[2-(1-Piperazinyl)ethoxy]ethanol 19059-68-8, 3-Dimethylamino-2,2-dimethyl-1-propanol 20691-89-8, (1-Methylpiperidin-4-yl)methanol 21156-84-3, 1-Methyl-4-piperidineethanol 22510-08-3, 2-Fluoro-5-nitrophenol 24313-88-0, 3,4,5-Trimethoxyaniline 80650-45-9, 4-(Pyridin-3-ylxy)phenylamine 98446-49-2, 2,4-Dichloro-5-methoxyaniline 168268-00-6, 4-Benzoyloxy-3-fluoroaniline 205194-33-8, 3-(1,1-Dioxothiomorpholinyl)-1-propanol 622369-58-8 622369-61-3 622369-80-6 622369-81-7, 1-Ethyl-4-(3-hydroxypropyl)piperazine 622369-83-9, 3-(1-Methylpiperidin-4-yl)propylamine

RL: RCT (Reactant); RACT (Reactant or reagent)

(process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

IT 380843-75-4P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]quinoline-3-carbonitrile 622368-76-7P 622368-77-8P 622368-78-9P 622368-79-0P 622368-80-3P 622368-81-4P 622368-82-5P 622368-83-6P 622368-84-7P 622368-85-8P 622368-86-9P 622368-87-0P 622368-88-1P 622368-89-2P 622368-90-5P 622368-91-6P 622368-92-7P 622368-93-8P 622368-94-9P 622368-95-0P 622368-96-1P 622368-97-2P 622368-98-3P 622368-99-4P 622369-00-0P 622369-01-1P 622369-02-2P 622369-03-3P 622369-04-4P 622369-05-5P 622369-06-6P 622369-07-7P 622369-08-8P 622369-09-9P 622369-10-2P 622369-11-3P 622369-12-4P 622369-13-5P 622369-14-6P 622369-15-7P 622369-16-8P 622369-17-9P 622369-18-0P 622369-19-1P 622369-20-4P 622369-21-5P 622369-22-6P 622369-23-7P 622369-24-8P 622369-25-9P 622369-26-0P 622369-27-1P 622369-28-2P 622369-29-3P 622369-30-6P 622369-31-7P 622369-32-8P 622369-33-9P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(morpholin-4-yl)propyl]amino]quinoline-3-carbonitrile 622369-34-0P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(quinoline product; process for preparation of 3-quinolinecarbonitriles via nucleophilic substitution)

L3 235 ANSWERS SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN AN 2005:1238736 SCISEARCH

GA The Genuine Article (R) Number: 986CG

TI Gene expression profile in the CML cell line K562 treated with SKI -606, a dual inhibitor of Src/Abl kinase.

CC HEMATOLOGY

L3 235 ANSWERS BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN TI The dual ABL/SRC inhibitors dasatinib, SKI-606, and INNO-406 are potent inhibitors of T cell acute lymphoblastic leukemia cell lines expressing the NUP214-ABL1 fusion kinase.

IT Methods & Equipment
 flow cytometry: laboratory techniques, histology and cytology techniques

IT Miscellaneous Descriptors
 apoptosis

L3 235 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

CC 1-6 (Pharmacology)

TI Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia

ST antitumor cSrc protein tyrosine kinase inhibitor pyrimidylaminobenzamide combination leukemia

IT Antitumor agents
 Chronic myeloid leukemia
 Combination chemotherapy
 Drug delivery systems
 Human
 Leukemia
 Veterinary medicine
 (use of c-Src inhibitors in combination with pyrimidylaminobenzamides for treatment of leukemia)

IT 144697-17-6, c-Src protein tyrosine kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; use of c-Src inhibitors in combination with pyrimidylaminobenzamides for treatment of leukemia)

IT 152459-95-5 172889-26-8 302962-49-8, Dasatinib 380843-75-4, Bosutinib 497152-38-2 641571-10-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of c-Src inhibitors in combination with pyrimidylaminobenzamides for treatment of leukemia)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d his

(FILE 'HOME' ENTERED AT 17:00:01 ON 27 APR 2008)

FILE 'REGISTRY' ENTERED AT 17:00:17 ON 27 APR 2008

L1 1 S SKI-606
 L2 1 S "SKI 606"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 17:04:21 ON 27 APR 2008

L3 235 S L2

=> s l3 and ischemia
 L4 6 L3 AND ISCHEMIA

=> s l3 and ("myocardial infarction")
 1 FILES SEARCHED...
 L5 2 L3 AND ("MYOCARDIAL INFARCTION")

=>

=> s l3 and angina
 L6 1 L3 AND ANGINA

=> dup rem l4 l5 l6
 PROCESSING COMPLETED FOR L4
 PROCESSING COMPLETED FOR L5

PROCESSING COMPLETED FOR L6

L7 6 DUP REM L4 L5 L6 (3 DUPLICATES REMOVED)
ANSWERS '1-3' FROM FILE CAPLUS
ANSWERS '4-6' FROM FILE EMBASE

=> d 17 1-6 hitstr ibib all

L7 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1


IT 380843-75-4, SKI-606

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(Src family tyrosine kinase inhibitor for treatment of myocardial
infarction)

RN 380843-75-4 CAPLUS

CN 3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-
7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



ACCESSION NUMBER: 2006:1209968 CAPLUS

DOCUMENT NUMBER: 145:500096

TITLE: Method using a Src family tyrosine kinase inhibitor
for the treatment of myocardial infarction

INVENTOR(S): Cheresch, David A.; Paul, Robert; Eliceiri, Brian
USA

PATENT ASSIGNEE(S):

SOURCE: U.S. Pat. Appl. Publ., 41pp., Cont.-in-part of U.S.
Ser. No. 298,377.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060258686	A1	20061116	US 2005-535325	20050518
WO 9961590	A1	19991202	WO 1999-US11780	19990528
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

US 6685938	B1	20040203	US 1999-470881	19991222
US 20030130209	A1	20030710	US 2002-298377	20021118
WO 2004045563	A2	20040603	WO 2003-US37653	20031118
WO 2004045563	A3	20041223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1998-87220P P 19980529
 WO 1999-US11780 A2 19990528
 US 1999-470881 A2 19991222
 US 2000-538248 A2 20000329
 US 2002-298377 A2 20021118
 WO 2003-US37653 W 20031118

AN 2006:1209968 CAPLUS
 DN 145:500096
 ED Entered STN: 17 Nov 2006
 TI Method using a Src family tyrosine kinase inhibitor for the treatment of myocardial infarction
 IN Cheresch, David A.; Paul, Robert; Eliceiri, Brian
 PA USA
 SO U.S. Pat. Appl. Publ., 4lpp., Cont.-in-part of U.S. Ser. No. 298,377.
 CODEN: USXXCO
 DT Patent
 LA English
 INCL 514262100
 CC 1-8 (Pharmacology)
 Section cross-reference(s): 63
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060258686	A1	20061116	US 2005-535325	20050518
	WO 9961590	A1	19991202	WO 1999-US11780	19990528
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6685938	B1	20040203	US 1999-470881	19991222
	US 20030130209	A1	20030710	US 2002-298377	20021118
	WO 2004045563	A2	20040603	WO 2003-US37653	20031118
	WO 2004045563	A3	20041223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI	US 1998-87220P	P	19980529
	WO 1999-US11780	A2	19990528
	US 1999-470881	A2	19991222
	US 2000-538248	A2	20000329
	US 2002-298377	A2	20021118
	WO 2003-US37653	W	20031118

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 20060258686	INCL	514262100
	IPCI	A61K0031-519 [I,A]
	IPCR	A61K0031-519 [I,C]; A61K0031-519 [I,A]
	NCL	514/262.100
WO 9961590	IPCI	C12N0009-00 [ICM,6]
	IPCR	C12N0015-09 [I,C*]; C12N0015-09 [I,A]; A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0048-00 [I,C*]; A61K0048-00 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0035-02 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C12N0009-12 [I,C*]; C12N0009-12 [I,A]
	ECLA	C12N009/12
US 6685938	IPCI	A61K0038-45 [ICM,7]; A61K0038-43 [ICM,7,C*]; A61K0038-17 [ICS,7]; C12N0009-12 [ICS,7]
	IPCR	A01K0067-027 [I,C*]; A01K0067-027 [I,A]; A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0038-43 [I,C*]; A61K0038-45 [I,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C12N0009-12 [I,C*]; C12N0009-12 [I,A]
	NCL	424/094.500; 435/194.000; 514/012.000
	ECLA	A01K067/027B; A61K038/45; C12N009/12
US 20030130209	IPCI	A61K0031-7048 [ICM,7]; A61K0031-7042 [ICM,7,C*]; A61K0031-519 [ICS,7]
	IPCR	A61K0038-43 [I,A]; A01K0067-027 [I,C*]; A01K0067-027 [I,A]; A61K0031-7088 [I,C*]; A61K0031-7088 [I,A]; A61K0035-66 [I,C*]; A61K0035-76 [I,A]; A61K0038-43 [I,C*]; A61K0038-45 [I,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; A61P0007-00 [I,C*]; A61P0007-00 [I,A]; A61P0009-00 [I,C*]; A61P0009-08 [I,A]; A61P0009-10 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-02 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]
	NCL	514/028.000; 514/262.100; 514/264.100; 514/265.100
	ECLA	A01K067/027B; A61K038/45
WO 2004045563	IPCI	A61K [ICM,7]
	IPCR	A61K0031-519 [I,C*]; A61K0031-519 [I,A]
AB	Myocardial infarction in a mammal is treated by administering to the mammal a therapeutically effective amount of a chemical Src family tyrosine kinase inhibitor. The invention also discloses the use of such inhibitors for the preparation of a medicament for treating myocardial infarction. Myocardial infarction can be prevented by administering to the mammal a prophylactic amount of the inhibitor. The inhibitor preferably is an inhibitor of Src protein selected from a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof. The Src family	

tyrosine kinase inhibitors can be used to prepare medicaments for the treatment of myocardial infarction. Also disclosed are articles of manufacture containing a chemical Src family tyrosine kinase inhibitor.

ST Src family tyrosine kinase inhibitor myocardial infarction treatment; pyrazolopyrimidine Src inhibitor myocardial infarction treatment; macrocyclic dienone Src inhibitor myocardial infarction treatment; pyridopyrimidine Src inhibitor myocardial infarction treatment; anilinoquinolinecarbonitrile Src inhibitor myocardial infarction treatment

IT Anti-ischemic agents
Cardiovascular agents
Drug delivery systems
Human
Platelet activation
Prophylaxis
(Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Src; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Platelet (blood)
(adhesion; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Ischemia
(cardiac; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Ischemia
(cerebral focal; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Blood vessel
(endothelium; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Heart, disease
(infarction; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Drug delivery systems
(injections, i.p.; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Drug delivery systems
(injections, i.v.; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Brain, disease
(ischemia, focal; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Heart, disease
(ischemia; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Macrocyclic compounds
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(macrocyclic dienones; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Drug delivery systems
(oral; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Drug delivery systems
(parenterals; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Blood vessel
(permeability; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Biological transport
(permeation, vascular; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Adhesion, biological
(platelet; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Endothelium
(vascular; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT Drugs
(veterinary; Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT 127464-60-2, VEGF 141349-87-3, Fyn kinase 141349-89-5, Src kinase 141349-91-9, Yes kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT 254-61-5D, Pyrido[2,3-d]pyrimidine, derivs. 12772-57-5, Radicicol R2146 30562-34-6, Geldanamycin 70563-58-5, Herbimycin A 172889-26-8 172889-27-9 260415-63-2, PD173955 380843-75-4, SKI-606 681215-57-6D, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

IT 915172-93-9 915172-95-1
RL: PRP (Properties)
(unclaimed nucleotide sequence; method using a Src family tyrosine kinase inhibitor for the treatment of myocardial infarction)


IT 915172-94-0 915172-96-2
RL: PRP (Properties)
(unclaimed protein sequence; method using a Src family tyrosine kinase inhibitor for the treatment of myocardial infarction)

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3

IT 380843-75-4, SKI-606
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

RN 380843-75-4 CAPLUS

CN 3-Quinolines carbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



ACCESSION NUMBER: 2004:331894 CAPLUS
 DOCUMENT NUMBER: 140:350577
 TITLE: Inhibition of src family kinases for the treatment of reperfusion injury related to revascularization
 Losordo, Douglas W.
 INVENTOR(S):
 PATENT ASSIGNEE(S): Caritas St. Elisabeth's Medical Center of Boston, Inc., USA
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032709	A2	20040422	WO 2003-US31430	20031003
WO 2004032709	A3	20041007		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500368	A1	20040422	CA 2003-2500368	20031003
AU 2003279795	A1	20040504	AU 2003-279795	20031003
US 20060167021	A1	20060727	US 2005-530038	20050401
PRIORITY APPLN. INFO.:				
			US 2002-416334P	P 20021004
			WO 2003-US31430	W 20031003

AN 2004:331894 CAPLUS
 DN 140:350577
 ED Entered STN: 23 Apr 2004
 TI Inhibition of src family kinases for the treatment of reperfusion injury related to revascularization
 Losordo, Douglas W.
 PA Caritas St. Elisabeth's Medical Center of Boston, Inc., USA
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61B
 CC 1-8 (Pharmacology)
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004032709	A2	20040422	WO 2003-US31430	20031003
WO 2004032709	A3	20041007		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

CA 2500368	A1	20040422	CA 2003-2500368	20031003
AU 2003279795	A1	20040504	AU 2003-279795	20031003
US 20060167021	A1	20060727	US 2005-530038	20050401
PRAI US 2002-416334P	P	20021004		
WO 2003-US31430	W	20031003		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004032709	ICM	A61B
	IPCI	A61B [ICM,7]
	IPCR	A61B [I,S]; A61K0031-47 [I,C*]; A61K0031-47 [I,A]
CA 2500368	IPCI	A61K0031-47 [ICM,7]
	IPCR	A61B [I,S]; A61K0031-47 [I,C*]; A61K0031-47 [I,A]
AU 2003279795	IPCI	A61K0031-47 [ICM,7]
	IPCR	A61B [I,S]; A61K0031-47 [I,C*]; A61K0031-47 [I,A]
US 20060167021	IPCI	A61K0031-519 [I,A]; A61K0031-47 [I,A]
	IPCR	A61K0031-519 [I,A]; A61K0031-47 [I,C]; A61K0031-47 [I,A]; A61K0031-519 [I,C]
	NCL	514/262.100; 514/313.000
AB	The invention provides methods for treating, preventing, or reducing reperfusion injury or post-pump syndrome by administering an inhibitor of vascular endothelial growth factor-mediated vascular permeability. The inhibitors of the invention include inhibitors of src family kinases.	
ST	VEGF mediated vascular permeability inhibitor revascularization reperfusion injury treatment; src kinase inhibitor revascularization reperfusion injury treatment	
IT	Heart, disease (angina pectoris, reperfusion injury from; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)	
IT	Medical goods (angioplasty balloon, coating for; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)	
IT	Edema Ischemia (cardiac; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)	
IT	Cardiovascular agents Cytoprotective agents (cardioprotective agents; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)	
IT	Disease, animal (compartment syndrome; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)	
IT	Artery (coronary, coronary revascularization procedure; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)	
IT	Heart, disease (edema; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)	
IT	Cadherins Catenins Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (flk-cadherin-catenin complex; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)	
IT	Heart, disease (infarction, reperfusion injury from; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)	
IT	Drug delivery systems (infusions; src family kinase inhibitors for treatment of reperfusion	

injury related to revascularization)

IT Drug delivery systems
(injections, i.p.; src family kinase inhibitors for treatment of
reperfusion injury related to revascularization)

IT Drug delivery systems
(injections, i.v.; src family kinase inhibitors for treatment of
reperfusion injury related to revascularization)

IT Drug delivery systems
(injections; src family kinase inhibitors for treatment of reperfusion
injury related to revascularization)

IT Reperfusion
(injury; src family kinase inhibitors for treatment of reperfusion
injury related to revascularization)

IT Drug delivery systems
(intracoronary; src family kinase inhibitors for treatment of
reperfusion injury related to revascularization)

IT Heart, disease
(ischemia; src family kinase inhibitors for treatment of
reperfusion injury related to revascularization)

IT Blood vessel, disease
(occlusion; src family kinase inhibitors for treatment of reperfusion
injury related to revascularization)

IT Drug delivery systems
(percutaneous; src family kinase inhibitors for treatment of
reperfusion injury related to revascularization)

IT Blood vessel
(permeability, VEGF-mediated; src family kinase inhibitors for
treatment of reperfusion injury related to revascularization)

IT Biological transport
(permeation, vascular, VEGF-mediated; src family kinase inhibitors for
treatment of reperfusion injury related to revascularization)

IT Disease, animal
(post-pump syndrome; src family kinase inhibitors for treatment of
reperfusion injury related to revascularization)

IT Ischemia
(reperfusion injury after; src family kinase inhibitors for treatment
of reperfusion injury related to revascularization)

IT Injury
(reperfusion; src family kinase inhibitors for treatment of reperfusion
injury related to revascularization)

IT Drug delivery systems
(solns., cardioplegic; src family kinase inhibitors for treatment of
reperfusion injury related to revascularization)

IT Angioplasty
Anti-ischemic agents
Atherectomy
Cardiovascular agents
Coronary bypass surgery
(src family kinase inhibitors for treatment of reperfusion injury
related to revascularization)

IT Medical goods
(stents, stent placement; src family kinase inhibitors for treatment of
reperfusion injury related to revascularization)

IT Brain, disease
(stroke; src family kinase inhibitors for treatment of reperfusion
injury related to revascularization)

IT 172889-26-8, PP 1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(PP 1; src family kinase inhibitors for treatment of reperfusion injury
related to revascularization)

IT 114051-78-4, Lck kinase 140208-17-9, Lyn kinase 141349-87-3, Fyn kinase 141349-89-5, Src kinase 141349-91-9, Yes kinase 145539-86-2, Hck kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

IT 34846-64-5D, 3-Quinolines carbonitrile, derivs. 64850-00-6D, Quinolines carbonitrile, derivs. 172889-27-9, PP2 380843-75-4, SKI-606 681215-57-6D, derivs.
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (src family kinase inhibitors for treatment of reperfusion injury related to revascularization)


IT 127464-60-2, Vascular endothelial growth factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (vascular permeability mediated by; src family kinase inhibitors for treatment of reperfusion injury related to revascularization)

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

IT 380843-75-4P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolines carbonitrile
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Src inhibitor; preparation of quinolines carbonitriles as Src inhibitors for treatment of ischemic injury)

RN 380843-75-4 CAPLUS

CN 3-Quinolines carbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



ACCESSION NUMBER: 2004:740166 CAPLUS
 DOCUMENT NUMBER: 141:243354
 TITLE: Preparation of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolines carbonitriles as Src inhibitors for the treatment of ischemic injury

INVENTOR(S): Boschelli, Diane Harris; Zaleska, Margaret Maria; Boschelli, Frank Charles; Arndt, Kim Timothy

PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA

SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004075898	A1	20040910	WO 2004-US4904	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040229880	A1	20041118	US 2004-780973	20040218
AU 2004216235	A1	20040910	AU 2004-216235	20040219
CA 2516418	A1	20040910	CA 2004-2516418	20040219
EP 1594502	A1	20051116	EP 2004-712889	20040219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007441	A	20060131	BR 2004-7441	20040219
CN 1750824	A	20060322	CN 2004-80004674	20040219
JP 2006522023	T	20060928	JP 2006-503706	20040219
IN 2005KN01564	A	20070126	IN 2005-KN1564	20050808
MX 2005PA08706	A	20051005	MX 2005-PA8706	20050816
NO 2005004070	A	20051114	NO 2005-4070	20050901
PRIORITY APPLN. INFO.:			US 2003-449316P	P 20030221
			WO 2004-US4904	A 20040219

OTHER SOURCE(S): MARPAT 141:243354

AN 2004:740166 CAPLUS

DN 141:243354

ED Entered STN: 10 Sep 2004

TI Preparation of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles as Src inhibitors for the treatment of ischemic injury

IN Boschelli, Diane Harris; Zaleska, Margaret Maria; Boschelli, Frank Charles; Arndt, Kim Timothy

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-496

ICS A61K031-4709; A61K031-4706; A61P009-10

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004075898	A1	20040910	WO 2004-US4904	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040229880	A1	20041118	US 2004-780973	20040218
AU 2004216235	A1	20040910	AU 2004-216235	20040219
CA 2516418	A1	20040910	CA 2004-2516418	20040219
EP 1594502	A1	20051116	EP 2004-712889	20040219

	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2004007441	A	20060131 BR 2004-7441 20040219
CN 1750824	A	20060322 CN 2004-80004674 20040219
JP 2006522023	T	20060928 JP 2006-503706 20040219
IN 2005KN01564	A	20070126 IN 2005-KN1564 20050808
MX 2005PA08706	A	20051005 MX 2005-PA8706 20050816
NO 2005004070	A	20051114 NO 2005-4070 20050901
PRAI US 2003-449316P	P	20030221
WO 2004-US4904	A	20040219

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004075898	ICM	A61K031-496
	ICS	A61K031-4709; A61K031-4706; A61P009-10
	IPCI	A61K0031-496 [ICM,7]; A61K0031-4709 [ICS,7]; A61K0031-4706 [ICS,7]; A61P009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]
	IPCR	A61K0031-4706 [I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61P009-00 [I,C*]; A61P0009-10 [I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]
	ECLA	A61K031/4706; A61K031/4709; A61K031/496; C07D215/54; C07D401/04+215+211; M07D
US 20040229880	IPCI	A61K0031-496 [ICM,7]; A61K0031-4709 [ICS,7]
	IPCR	A61K0031-4706 [I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]
	NCL	514/253.060; 514/313.000
	ECLA	A61K031/4706; A61K031/4709; A61K031/496; C07D215/54; C07D401/04+215+211
AU 2004216235	IPCI	A61K0031-496 [ICM,7]; A61K0031-4709 [ICS,7]; A61K0031-4706 [ICS,7]; A61P009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]
	IPCR	A61K0031-4706 [I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61P009-00 [I,C*]; A61P0009-10 [I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]
CA 2516418	IPCI	A61K0031-496 [ICM,7]; A61P0009-10 [ICS,7]; A61P009-00 [ICS,7,C*]; A61K0031-4706 [ICS,7]; A61K0031-4709 [ICS,7]
	IPCR	A61K0031-4706 [I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61P009-00 [I,C*]; A61P0009-10 [I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]
	ECLA	A61K031/4706; A61K031/4709; A61K031/496; C07D215/54; C07D401/04+215+211
EP 1594502	IPCI	A61K0031-496 [ICM,7]; A61K0031-4709 [ICS,7]; A61K0031-4706 [ICS,7]; A61P009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]
	IPCR	A61K0031-4706 [I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61P009-00 [I,C*]; A61P0009-10 [I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]
	ECLA	A61K031/4706; A61K031/4709; A61K031/496; C07D215/54;

C07D401/04+215+211

BR 2004007441 IPCI A61K0031-496 [ICS,7]; A61K0031-4706 [ICS,7];
A61K0031-4709 [ICS,7]; A61P0009-10 [ICS,7]; A61P0009-00
[ICS,7,C*]

IPCR A61K0031-4706 [I,C*]; A61K0031-4709 [I,C*];
A61K0031-496 [I,C*]; C07D0215-00 [I,C*]; C07D0401-00
[I,C*]; A61K0031-4706 [I,A]; A61K0031-4709 [I,A];
A61K0031-496 [I,A]; C07D0215-54 [I,A]; C07D0401-04
[I,A]

ECLA A61K031/4706; A61K031/4709; A61K031/496; C07D215/54;
C07D401/04+215+211

CN 1750824 IPCI A61K0031-496 [I,A]; A61K0031-4709 [I,A]; A61K0031-4706
[I,A]; A61P0009-10 [I,A]; A61P0009-00 [I,C*]

IPCR A61K0031-496 [I,A]; A61K0031-4706 [I,C*]; A61K0031-4706
[I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A];
A61K0031-496 [I,C]; A61P0009-00 [I,C*]; A61P0009-10
[I,A]; C07D0215-00 [I,C*]; C07D0215-54 [I,A];
C07D0401-00 [I,C*]; C07D0401-04 [I,A]

ECLA A61K031/4706; A61K031/4709; A61K031/496; C07D215/54;
C07D401/04+215+211

JP 2006522023 IPCI A61K0031-4709 [I,A]; A61P0009-10 [I,A]; A61P0009-00
[I,C*]; A61P0025-00 [I,A]; A61P0043-00 [I,A];
C07D0215-54 [N,A]; C07D0215-00 [N,C*]; C12N0015-09
[N,A]; C07D0401-12 [N,A]; C07D0401-00 [N,C*]

IPCR A61K0031-4709 [I,C]; A61K0031-4709 [I,A]; A61K0031-4706
[I,C*]; A61K0031-4706 [I,A]; A61K0031-496 [I,C*];
A61K0031-496 [I,A]; A61P0009-00 [I,C]; A61P0009-10
[I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A];
A61P0043-00 [I,C]; A61P0043-00 [I,A]; C07D0215-00
[I,C*]; C07D0215-54 [I,A]; C07D0401-00 [I,C*];
C07D0401-04 [I,A]; C07D0401-12 [N,A]; C12N0015-09
[N,C]; C12N0015-09 [N,A]

FTERM 4B024/AA11; 4B024/BA10; 4B024/CA04; 4B024/CA20;
4B024/DA02; 4B024/EA04; 4B024/HA11; 4C031/NA05;
4C063/AA01; 4C063/BB08; 4C063/CC14; 4C063/DD10;
4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA04;
4C086/BC28; 4C086/GA12; 4C086/MA01; 4C086/MA04;
4C086/NA14; 4C086/ZA02; 4C086/ZA36; 4C086/ZC20



IN 2005KN01564 IPCI A61K0031-496 [ICM,7]; A61K0031-4709 [ICS,7];
A61P0009-10 [ICS,7]; A61P0009-00 [ICS,7,C*]

MX 2005PA08706 IPCI A61K0031-4706 [ICM,7]; A61K0031-4709 [ICS,7];
A61K0031-496 [ICS,7]; A61P0009-10 [ICS,7]; A61P0009-00
[ICS,7,C*]

NO 2005004070 IPCR A61K0031-4706 [I,C*]; A61K0031-4706 [I,A];
A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496
[I,C*]; A61K0031-496 [I,A]; A61P0009-00 [I,C*];
A61P0009-10 [I,A]; C07D0215-00 [I,C*]; C07D0215-54
[I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]

ECLA A61K031/4706; A61K031/4709; A61K031/496; C07D215/54;
C07D401/04+215+211

OS MARPAT 141:243354
GI



- AB Title compds. I [wherein X = N, CH; n = 1-3; R', R = independently Cl-3 alkyl; with the proviso that when n = 1, X ≠ N; and pharmaceutically acceptable salts thereof] were prepared as Src inhibitors. Compds. of the invention and their pharmaceutical compns. provide neuroprotection, inhibit neurol. deficits, reduce infarct vols., and inhibit post-ischemic vascular permeability following an ischemic event. For example, amination of 7-(3-chloropropoxy)-4-[(2,4-dichloro-5-methoxyphenyl)aminol]-6-methoxy-3-quinolinecarbonitrile with N-methylpiperazine provided II (75%). The latter suppressed Src tyrosine kinase activity (IC50 = 1.2 nM) and inhibited Src dependent cell proliferation in Rat2 fibroblasts stably transformed with a plasmid containing the catalytic domain of human c-Src (IC50 = 100 nM). In a transient model of focal ischemia using Wistar rats, administration of II at doses of 3, 10, and 30 mg/kg (IV) resulted in reduction of brain tissue infarction volume by 22%, 53%, and 42%, resp., and reduction of stroke-induced neurol. deficits as measured by mean motor deficit scores. In a model producing extensive infarction to sensorimotor cortex with quant. assessment of neurol. deficits for 21 days post-stroke, II provided significant improvement in the neurol. outcome.
- ST quinolinecarbonitrile prepn Src inhibitor ischemic injury treatment neuroprotectant
- IT Heart, disease
(arrest; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)
- IT Brain, disease
(hemorrhagic stroke; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)
- IT Brain, disease
(infarction; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)
- IT Drug delivery systems
(injections, i.v.; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)
- IT Brain, disease

(ischemia, transient; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT Cytoprotective agents
Nervous system agents
(neuroprotective agents; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT Asphyxia
(perinatal; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT Blood vessel
(permeability; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT Anti-ischemic agents
Drug delivery systems
Human
Hypoxia
Ischemia
(preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT Epilepsy
(status epilepticus; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT Brain, disease
(stroke; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT Ischemia
(transient cerebral; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT Head and Neck, disease
Spinal cord, disease
(trauma; preparation of quinolinecarbonitriles as Src inhibitors for treatment of ischemic injury)

IT 380843-75-4P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile
380843-76-5P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[3-(4-ethyl-1-piperazinyl)propoxy]-6-methoxy-3-quinolinecarbonitrile 380843-79-8P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-propyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile 622368-88-1P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]-3-quinolinecarbonitrile 622368-91-6P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-3-quinolinecarbonitrile 622369-21-5P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile 622369-25-9P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[(1-ethylpiperidin-4-yl)methoxy]-6-methoxyquinoline-3-carbonitrile 753005-88-8P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-3-quinolinecarbonitrile 753005-89-9P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[2-(4-ethyl-1-piperazinyl)ethoxy]-6-methoxy-3-quinolinecarbonitrile 753005-90-2P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile 753005-91-3P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile 753005-92-4P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(4-ethylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile 753005-93-5P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile 753005-94-6P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]quinoline-3-carbonitrile 753005-95-7P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Src inhibitor; preparation of quinolinecarboxitriles as Src inhibitors for treatment of ischemic injury)

IT 622369-35-1P, Ethyl 7-fluoro-6-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylate 622369-36-2P, 7-Fluoro-6-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid 622369-37-3P, 7-Fluoro-6-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxamide 622369-38-4P, 7-Fluoro-6-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxitrile 622369-40-8P, 4-Chloro-7-fluoro-6-methoxy-3-quinolinecarboxitrile 622369-46-4P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-fluoro-6-methoxy-3-quinolinecarboxitrile 622369-50-0P, 6-Benzyloxy-7-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxitrile 622369-51-1P, 6-Benzyloxy-4-chloro-7-fluoro-3-quinolinecarboxitrile 622369-52-2P, 4-Chloro-7-fluoro-6-hydroxy-3-quinolinecarboxitrile 622369-53-3P, 4-Chloro-6-ethoxy-7-fluoro-3-quinolinecarboxitrile 622369-82-8P, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-fluoro-3-quinolinecarboxitrile
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of quinolinecarboxitriles as Src inhibitors for treatment of ischemic injury)

IT 141349-89-5, Src kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of quinolinecarboxitriles as Src inhibitors for treatment of ischemic injury)

IT 87-13-8, Diethyl (ethoxymethylene)malonate 94-05-3, Ethyl 2-(ethoxymethylene)-2-cyanoacetate 109-01-3, N-Methylpiperazine 366-99-4, 3-Fluoro-4-methoxyaniline 5308-25-8, N-Ethylpiperazine 5317-33-9, 3-(4-Methylpiperazin-1-yl)propanol 5464-12-0, 2-(4-Methyl-1-piperazinyl)ethanol 7037-30-1, 3-(1-Methyl-4-piperidinyl)propanol 20691-89-8, 1-Methylpiperidine-4-methanol 21156-84-3, 1-Methyl-4-piperidineethanol 21867-64-1, N-Propylpiperazine 98446-49-2, 2,4-Dichloro-5-methoxyaniline 168268-00-6, 4-Benzyloxy-3-fluoroaniline 380844-42-8, 7-(2-Chloroethoxy)-4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-3-quinolinecarboxitrile 380844-49-5, 7-(3-Chloropropoxy)-4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-3-quinolinecarboxitrile 622369-81-7, 3-(4-Ethylpiperazin-1-yl)propanol
RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of quinolinecarboxitriles as Src inhibitors for treatment of ischemic injury)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) American Home Products Co; US 2002026052 A1 2002
- (2) Berger, D; BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 2001, V12(20), P2989
- (3) Boschelli, D; BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 2003, V13(21), P3797 CAPLUS
- (4) Caritas St Elisabeth's Medical Centre Of Boston Inc; WO 2004032709 A 2004 CAPLUS
- (5) Paul, R; NATURE MEDICINE 2001, V7(2), P222 CAPLUS
- (6) Wyeth Holdings Co; WO 03093241 A 2003 CAPLUS

L7 ANSWER 4 OF 6 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN DUPLICATE 2

ACCESSION NUMBER: 2006365755 EMBASE

TITLE: Src protein tyrosine kinase family and acute inflammatory responses.

AUTHOR: Liu, Mingyao (correspondence)

CORPORATE SOURCE: School of Graduate Studies, Univ. of Toronto, 65 St. George St., Toronto, Ont. M5S 2Z9, Canada. mingyao.liu@utoronto.ca

AUTHOR: Okutani, Daisuke; Lodyga, Monika; Han, Bing

SOURCE: American Journal of Physiology - Lung Cellular and Molecular Physiology, (2006) Vol. 291, No. 2, pp. L129-L141.
 Refs: 154
 ISSN: 1040-0605 E-ISSN: 1522-1504 CODEN: APLPE7
 COUNTRY: United States
 DOCUMENT TYPE: Journal; General Review; (Review)
 FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
 029 Clinical and Experimental Biochemistry
 030 Clinical and Experimental Pharmacology
 037 Drug Literature Index
 005 General Pathology and Pathological Anatomy
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 15 Aug 2006
 Last Updated on STN: 15 Aug 2006
 AN 2006365755 EMBASE
 TI Src protein tyrosine kinase family and acute inflammatory responses.
 AU Liu, Mingyao (correspondence)
 CS School of Graduate Studies, Univ. of Toronto, 65 St. George St., Toronto, Ont. M5S 2Z9, Canada. mingyao.liu@utoronto.ca
 AU Okutani, Daisuke; Lodyga, Monika; Han, Bing
 SO American Journal of Physiology - Lung Cellular and Molecular Physiology, (2006) Vol. 291, No. 2, pp. L129-L141.
 Refs: 154
 ISSN: 1040-0605 E-ISSN: 1522-1504 CODEN: APLPE7
 CY United States
 DT Journal; General Review; (Review)
 FS 015 Chest Diseases, Thoracic Surgery and Tuberculosis
 029 Clinical and Experimental Biochemistry
 030 Clinical and Experimental Pharmacology
 037 Drug Literature Index
 005 General Pathology and Pathological Anatomy
 LA English
 SL English
 ED Entered STN: 15 Aug 2006
 Last Updated on STN: 15 Aug 2006
 AB Acute inflammatory responses are one of the major underlying mechanisms for tissue damage of multiple diseases, such as ischemia-reperfusion injury, sepsis, and acute lung injury. By use of cellular and molecular approaches and transgenic animals, Src protein tyrosine kinase (PTK) family members have been identified to be essential for the recruitment and activation of monocytes, macrophages, neutrophils, and other immune cells. Src PTKs also play a critical role in the regulation of vascular permeability and inflammatory responses in tissue cells. Importantly, animal studies have demonstrated that small chemical inhibitors for Src PTKs attenuate tissue injury and improve survival from a variety of pathological conditions related to acute inflammatory responses. Further investigation may lead to the clinical application of these inhibitors as drugs for ischemia-reperfusion injury (such as stroke and myocardial infarction), sepsis, acute lung injury, and multiple organ dysfunction syndrome. Copyright .COPYRG. 2006 the American Physiological Society.
 CT Medical Descriptors:
 acute lung injury: DT, drug therapy
 antiinflammatory activity
 blood vessel permeability
 brain injury: DT, drug therapy
 brain ischemia: DT, drug therapy
 drug inhibition
 drug protein binding

endotoxemia
epithelium cell
heart infarction: DT, drug therapy
human
*inflammation
ischemia
leukocyte activation
lung transplantation
macrophage activation
*multiple organ failure
nonhuman
priority journal
reperfusion injury
*respiratory distress
review
sepsis
spinal cord compression: DT, drug therapy
stroke: DT, drug therapy
virus infection

CT

Drug Descriptors:
2,3 dihydro 2 oxo 3 (4,5,6,7 tetrahydro 1h indol 2 ylmethylene) 1h indole
5 sulfonic acid dimethylamide: DT, drug therapy
2,3 dihydro 2 oxo 3 (4,5,6,7 tetrahydro 1h indol 2 ylmethylene) 1h indole
5 sulfonic acid dimethylamide: IP, intraperitoneal drug administration
2,3 dihydro 2 oxo 3 (4,5,6,7 tetrahydro 1h indol 2 ylmethylene) 1h indole
5 sulfonic acid dimethylamide: PD, pharmacology
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 1:
DT, drug therapy
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 1:
IP, intraperitoneal drug administration
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 1:
PD, pharmacology
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 2:
DT, drug therapy
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 2:
IP, intraperitoneal drug administration
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 2:
IV, intravenous drug administration
4 amino 5 (4 methylphenyl) 7 (tert butyl) pyrazolo[3,4 d] pyrimidine 2:
PD, pharmacology
azm 475271: PD, pharmacology
bosutinib: PD, pharmacology
CD14 antigen: EC, endogenous compound
cgp 76030: PD, pharmacology
cgp 77675: PD, pharmacology
cytokine: EC, endogenous compound
gamma interferon: EC, endogenous compound
hematopoietic cell kinase: EC, endogenous compound
immunoglobulin enhancer binding protein: EC, endogenous compound
interleukin 1: EC, endogenous compound
interleukin 6: EC, endogenous compound
m 47271
m 475271: PD, pharmacology
mitogen activated protein kinase 1: EC, endogenous compound
mitogen activated protein kinase 3: EC, endogenous compound
protein kinase: EC, endogenous compound
protein kinase Blk: EC, endogenous compound
protein kinase fgr: EC, endogenous compound
protein kinase Fyn: EC, endogenous compound
protein kinase Lck: EC, endogenous compound
protein kinase Lyn: EC, endogenous compound

protein kinase Yes: EC, endogenous compound
 protein kinase Yrk: EC, endogenous compound
 *protein tyrosine kinase: EC, endogenous compound
 *protein tyrosine kinase inhibitor: DT, drug therapy
 *protein tyrosine kinase inhibitor: IP, intraperitoneal drug
 administration
 *protein tyrosine kinase inhibitor: IV, intravenous drug administration
 *protein tyrosine kinase inhibitor: PD, pharmacology
 toll like receptor 4: EC, endogenous compound
 tumor necrosis factor alpha: EC, endogenous compound
 unclassified drug
 vasculotropin: EC, endogenous compound
 RN (bosutinib) 380843-75-4; (gamma interferon) 82115-62-6; (mitogen
 activated protein kinase 1) 137632-08-7; (mitogen activated protein kinase
 3) 137632-07-6; (protein kinase Fyn) 141349-87-3; (protein kinase Lck)
 114051-78-4; (protein kinase Lyn) 140208-17-9; (protein kinase) 9026-43-1;
 (protein tyrosine kinase) 80449-02-1; (toll like receptor 4) 203811-83-0;
 (vasculotropin) 127464-60-2
 CN azm 475271; cgp 76030; cgp 77675; m 47271; ski 606; su 6656

L7 ANSWER 5 OF 6 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights
 reserved on STN

ACCESSION NUMBER: 2007392630 EMBASE
 TITLE: Bosutinib. Dual Src and Abl kinase inhibitor treatment of
 solid tumors treatment of CML and Ph(+) all.
 AUTHOR: Boschelli, Diane H. (correspondence); Boschelli, Frank
 CORPORATE SOURCE: Wyeth Research, 401 N. Middletown Road, Pearl River, NY
 10956, United States.
 SOURCE: Drugs of the Future, (Jun 2007) Vol. 32, No. 6, pp.
 481-490.
 Refs: 64
 ISSN: 0377-8282 CODEN: DRFUD4
 COUNTRY: Spain
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 016 Cancer
 025 Hematology
 030 Clinical and Experimental Pharmacology
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 23 Aug 2007
 Last Updated on STN: 23 Aug 2007

AN 2007392630 EMBASE
 TI Bosutinib. Dual Src and Abl kinase inhibitor treatment of solid tumors
 treatment of CML and Ph(+) all.
 AU Boschelli, Diane H. (correspondence); Boschelli, Frank
 CS Wyeth Research, 401 N. Middletown Road, Pearl River, NY 10956, United
 States.
 SO Drugs of the Future, (Jun 2007) Vol. 32, No. 6, pp. 481-490.
 Refs: 64
 ISSN: 0377-8282 CODEN: DRFUD4
 CY Spain
 DT Journal; Article
 FS 016 Cancer
 025 Hematology
 030 Clinical and Experimental Pharmacology
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LA English
 SL English

ED Entered STN: 23 Aug 2007
 Last Updated on STN: 23 Aug 2007

AB Bosutinib (SKI-606) is a potent inhibitor of Src kinase activity, having IC(50) values of 1-3 nM in isolated Src enzyme assays. Bosutinib inhibits Src autophosphorylation and the phosphorylation of several known Src substrate proteins in multiple human cancer lines. Bosutinib is orally effective in nude mouse xenograft models, including HT-29, COLO 205, HCT 116 and DLD-1 colorectal tumors and MDA-MB-231 breast tumors, as well as in several in vivo models of metastasis. Like many other Src inhibitors, bosutinib is also a potent inhibitor of Abl kinase activity, having an IC(50) of 1 nM in an enzyme assay. It is a potent antiproliferative agent in chronic myelogenous leukemia (CML) cell lines and inhibits the phosphorylation of Abl substrate proteins in these cells. A 5-day oral regimen of bosutinib caused tumor regression and some cures in a CML xenograft model. Bosutinib was also orally active in models of imatinib-resistant CML. Bosutinib is currently in clinical trials for the treatment of both solid tumors and CML. Copyright .COPYRGT. 2007 Prous science.

CT Medical Descriptors:
 article
 bone metastasis: DT, drug therapy
 brain ischemia: DT, drug therapy
 breast metastasis: DT, drug therapy
 breast tumor
 chronic myeloid leukemia: DR, drug resistance
 chronic myeloid leukemia: DT, drug therapy
 clinical trial
 colorectal tumor
 diarrhea: SI, side effect
 dose response
 drug bioavailability
 drug blood level
 drug distribution
 drug half life
 drug metabolism
 drug stability
 drug structure
 drug synthesis
 human
 lung edema: SI, side effect
 nausea: SI, side effect
 nonhuman
 pleura effusion: SI, side effect
 rash: SI, side effect
 tumor regression
 xenograft

CT Drug Descriptors:
 Abelson kinase: EC, endogenous compound
 *bosutinib: AE, adverse drug reaction
 *bosutinib: CT, clinical trial
 *bosutinib: AN, drug analysis
 *bosutinib: CM, drug comparison
 *bosutinib: CR, drug concentration
 *bosutinib: DV, drug development
 *bosutinib: DO, drug dose
 *bosutinib: DT, drug therapy
 *bosutinib: IP, intraperitoneal drug administration
 *bosutinib: PK, pharmacokinetics
 *bosutinib: PD, pharmacology
 dasatinib: AE, adverse drug reaction
 dasatinib: CM, drug comparison

dasatinib: DT, drug therapy
dasatinib: PD, pharmacology
fibroblast growth factor receptor: EC, endogenous compound
imatinib: AE, adverse drug reaction
imatinib: CM, drug comparison
imatinib: DT, drug therapy
imatinib: PD, pharmacology
platelet derived growth factor receptor: EC, endogenous compound
somatomedin C receptor: EC, endogenous compound

RN (bosutinib) 380843-75-4; (dasatinib) 302962-49-8; (fibroblast
growth factor receptor) 153424-51-2; (imatinib) 152459-95-5, 220127-57-1
CN (1) gleevec; (2) glivec; (3) sprycel; ski 606
CO (1) Novartis; (2) Novartis; (3) Bristol Myers Squibb

L7 ANSWER 6 OF 6 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights
reserved on STN

ACCESSION NUMBER: 2008025607 EMBASE
TITLE: Mutational analysis and overcoming imatinib resistance in
chronic myeloid leukemia with novel tyrosine kinase
inhibitors.

AUTHOR: Mauro, Michael J., Dr. (correspondence)
CORPORATE SOURCE: Center for Hematologic Malignancies, Oregon Health and
Science University, Portland, OR 97239, United States.
maurom@ohsu.edu

SOURCE: Current Treatment Options in Oncology, (Aug 2007) Vol. 8,
No. 4, pp. 287-295.
Refs: 30
ISSN: 1527-2729 CODEN: CTOOBW

COUNTRY: United States
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 016 Cancer
025 Hematology
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English
ENTRY DATE: Entered STN: 13 Feb 2008
Last Updated on STN: 13 Feb 2008

AN 2008025607 EMBASE
TI Mutational analysis and overcoming imatinib resistance in chronic myeloid
leukemia with novel tyrosine kinase inhibitors.

AU Mauro, Michael J., Dr. (correspondence)
CS Center for Hematologic Malignancies, Oregon Health and Science University,
Portland, OR 97239, United States. maurom@ohsu.edu

SO Current Treatment Options in Oncology, (Aug 2007) Vol. 8, No. 4, pp.
287-295.
Refs: 30
ISSN: 1527-2729 CODEN: CTOOBW

CY United States
DT Journal; General Review; (Review)
FS 016 Cancer
025 Hematology
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles

LA English
ED Entered STN: 13 Feb 2008
Last Updated on STN: 13 Feb 2008

CT Medical Descriptors:
arthralgia: SI, side effect
blast cell crisis: SI, side effect

blood toxicity: SI, side effect
 bone marrow suppression: SI, side effect
 cardiotoxicity: SI, side effect
 *chronic myeloid leukemia: DR, drug resistance
 *chronic myeloid leukemia: DT, drug therapy
 clinical trial
 diarrhea: SI, side effect
 dosage schedule comparison
 drug cross tolerance
 drug dose comparison
 drug efficacy
 drug half life
 drug induced headache: SI, side effect
 drug megadose
 drug penetration
 drug response
 drug tolerability
 ECG abnormality: SI, side effect
 edema: SI, side effect
 fatigue: SI, side effect
 fluid retention
 gastrointestinal hemorrhage: SI, side effect
 heart arrhythmia: SI, side effect
 heart disease: SI, side effect
 human
 hyperglycemia: SI, side effect
 hypocalcemia: SI, side effect
 hypophosphatemia: SI, side effect
 ischemia: SI, side effect
 *mutational analysis
 myalgia: SI, side effect
 neutropenia: SI, side effect
 pancreatitis: SI, side effect
 pleura effusion: DT, drug therapy
 pleura effusion: SI, side effect
 pleura effusion: SU, surgery
 pruritus: SI, side effect
 QT prolongation: SI, side effect
 rash: SI, side effect
 review
 salvage therapy
 side effect: SI, side effect
 structure activity relation
 subdural hematoma: SI, side effect
 thorax drainage
 thrombocytopenia: SI, side effect
 treatment failure

CT

Drug Descriptors:
 4 (3 dimethylamino 1 pyrrolidinylmethyl) 3 trifluoromethyl n [4 methyl 3
 [[4 (5 pyrimidinyl) 2 pyrimidinyl]amino]phenyl]benzamide: CT, clinical
 trial
 4 (3 dimethylamino 1 pyrrolidinylmethyl) 3 trifluoromethyl n [4 methyl 3
 [[4 (5 pyrimidinyl) 2 pyrimidinyl]amino]phenyl]benzamide: DT, drug therapy
 4 (3 dimethylamino 1 pyrrolidinylmethyl) 3 trifluoromethyl n [4 methyl 3
 [[4 (5 pyrimidinyl) 2 pyrimidinyl]amino]phenyl]benzamide: PK,
 pharmacokinetics
 4 (3 dimethylamino 1 pyrrolidinylmethyl) 3 trifluoromethyl n [4 methyl 3
 [[4 (5 pyrimidinyl) 2 pyrimidinyl]amino]phenyl]benzamide: PD, pharmacology
 antineoplastic agent: CT, clinical trial
 antineoplastic agent: DT, drug therapy
 antineoplastic agent: PK, pharmacokinetics

antineoplastic agent: PD, pharmacology
 BCR ABL protein: EC, endogenous compound
 bosutinib: AE, adverse drug reaction
 bosutinib: CT, clinical trial
 bosutinib: DT, drug therapy
 bosutinib: PD, pharmacology
 cyclopropanecarboxylic acid [4 [4 (4 methyl 1 piperazinyl) 6 (5 methyl 2h
 pyrazol 3 ylamino) 2 pyrimidinylthio]phenyl]amide: CT, clinical trial
 cyclopropanecarboxylic acid [4 [4 (4 methyl 1 piperazinyl) 6 (5 methyl 2h
 pyrazol 3 ylamino) 2 pyrimidinylthio]phenyl]amide: DT, drug therapy
 cytarabine: CT, clinical trial
 cytarabine: CM, drug comparison
 cytarabine: DT, drug therapy
 dasatinib: AE, adverse drug reaction
 dasatinib: CT, clinical trial
 dasatinib: CM, drug comparison
 dasatinib: CR, drug concentration
 dasatinib: DO, drug dose
 dasatinib: DT, drug therapy
 dasatinib: PK, pharmacokinetics
 dasatinib: PD, pharmacology
 diuretic agent: DT, drug therapy
 gamma interferon: CT, clinical trial
 gamma interferon: CM, drug comparison
 gamma interferon: DT, drug therapy
 *imatinib: CT, clinical trial
 *imatinib: CM, drug comparison
 *imatinib: DO, drug dose
 *imatinib: DT, drug therapy
 *imatinib: PD, pharmacology
 nilotinib: AE, adverse drug reaction
 nilotinib: CT, clinical trial
 nilotinib: CM, drug comparison
 nilotinib: DT, drug therapy
 nilotinib: PD, pharmacology
 *protein tyrosine kinase inhibitor: CT, clinical trial
 *protein tyrosine kinase inhibitor: DT, drug therapy
 *protein tyrosine kinase inhibitor: PD, pharmacology
 threonine: EC, endogenous compound
 RN (bosutinib) 380843-75-4; (cyclopropanecarboxylic acid [4 [4 (4
 methyl 1 piperazinyl) 6 (5 methyl 2h pyrazol 3 ylamino) 2
 pyrimidinylthio]phenyl]amide) 639089-54-6; (cytarabine) 147-94-4, 69-74-9;
 (dasatinib) 302962-49-8; (gamma interferon) 82115-62-6; (imatinib)
 152459-95-5, 220127-57-1; (nilotinib) 641571-10-0; (threonine) 36676-50-3,
 72-19-5
 CN amn 107; ara C; bms 354825; inno 406; ski 606; sti 571

=> d his

(FILE 'HOME' ENTERED AT 17:00:01 ON 27 APR 2008)

FILE 'REGISTRY' ENTERED AT 17:00:17 ON 27 APR 2008

L1 1 S SKI-606
 L2 1 S "SKI 606"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 17:04:21 ON
 27 APR 2008

L3 235 S L2
 L4 6 S L3 AND ISCHEMIA
 L5 2 S L3 AND ("MYOCARDIAL INFARCTION")

L6
L7

1 S L3 AND ANGINA
6 DUP REM L4 L5 L6 (3 DUPLICATES REMOVED)